CeriBell, Inc. (CBLL)
| Market Cap | 787.75M |
| Revenue (ttm) | 89.06M |
| Net Income (ttm) | -53.41M |
| Shares Out | 37.87M |
| EPS (ttm) | -1.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 160,890 |
| Open | 21.09 |
| Previous Close | 21.14 |
| Day's Range | 20.66 - 21.20 |
| 52-Week Range | 10.85 - 24.33 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 23.20 (+11.54%) |
| Earnings Date | May 11, 2026 |
About CBLL
CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company also offers disposable, flexible headbands, and headcaps; and a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly transmit EEG signals; and Clarity, an AI-powered seizure detection algorithm. In addition, it operates an EEG portal, which enables real-time remote acc... [Read more]
Financial Performance
In 2025, CeriBell's revenue was $89.06 million, an increase of 36.09% compared to the previous year's $65.44 million. Losses were -$53.41 million, 32.0% more than in 2024.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for CBLL stock is "Strong Buy." The 12-month stock price target is $23.2, which is an increase of 11.54% from the latest price.
News
Ceribell to Report First Quarter 2026 Financial Results on May 11, 2026
SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with ser...
CeriBell Transcript: TD Cowen 46th Annual Health Care Conference
Consistent outperformance and strong 2026 growth guidance are supported by sales force expansion, new neonatal/pediatric launches, and entry into the VA system. Delirium monitoring and continuous product innovation further differentiate offerings, while gross margins remain robust.
CeriBell Transcript: 47th Annual Raymond James Institutional Investor Conference
A novel rapid EEG platform with AI-driven seizure detection achieved $89M in 2025 revenue and 36% growth, expanding its market with pediatric, neonate, and delirium indications. With only 3% U.S. market penetration, the company is focused on deeper hospital adoption, new indications, and leveraging its platform for future growth.
CeriBell Earnings Call Transcript: Q4 2025
Delivered 36% revenue growth in 2025, expanded TAM to $3.5B, and achieved key FDA clearances for new indications. 2026 guidance calls for 25–29% revenue growth, with new product launches and deeper account penetration expected to drive upside.
Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results
SUNNYVALE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
Ceribell to Participate in Upcoming March Investor Conferences
SUNNYVALE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
CeriBell Transcript: 44th Annual J.P. Morgan Healthcare Conference
Ceribell showcased strong growth, expanding its neuromonitoring platform's reach with FDA clearances for pediatric, neonate, and delirium detection, increasing its TAM to $3.5B. The company plans to leverage its expanded sales force and new product launches in 2026, aiming for deeper market penetration and operational efficiency.
Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution
SUNNYVALE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference
SUNNYVALE, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution
SUNNYVALE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
CeriBell Transcript: Piper Sandler 37th Annual Healthcare Conference
A novel neuro monitoring platform with AI-driven seizure detection is driving rapid growth, improved clinical outcomes, and expanding market reach in acute care. The company is focused on US expansion, new indications, and leveraging its first-mover advantage.
Ceribell Receives FDA 510(k) Clearance for Use of ClarityⓇ Algorithm for Neonates
Becomes the first and only FDA-cleared seizure detection algorithm for pre-term neonates through adults enabling rapid bedside detection, diagnosis, and treatment of non-convulsive seizures Becomes th...
CeriBell Transcript: CG MedTech, Diagnostics and Digital Health & Services Forum
A novel EEG monitoring system is driving rapid growth, with strong financials, expanding hospital adoption, and a robust sales pipeline. Strategic manufacturing shifts and a defensible AI-driven algorithm support long-term profitability and market leadership.
Ceribell to Participate in the Piper Sandler 37th Annual Healthcare Conference
SUNNYVALE, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
SUNNYVALE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
CeriBell Earnings Call Transcript: Q3 2025
Q3 2025 revenue grew 31% year-over-year to $22.6M, with strong account and utilization growth. Full-year guidance was raised to $87–$89M, and gross margins remain robust despite tariff headwinds. Expansion into pediatric, neonatal, and VA markets, plus new product clearances, support a strong growth outlook.
Ceribell Reports Third Quarter 2025 Financial Results
SUNNYVALE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
Ceribell to Report Third Quarter 2025 Financial Results on November 4, 2025
SUNNYVALE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
Medtech Leader Erica Rogers Joins Ceribell Board of Directors
Accomplished innovator and healthcare executive brings proven strategic leadership and expertise in scaling high-growth healthcare companies Accomplished innovator and healthcare executive brings prov...
CeriBell Transcript: Canaccord Genuity’s 45th Annual Growth Conference
An AI-powered EEG platform is driving rapid growth in acute care seizure detection, with strong clinical impact and only 3% market penetration. Expansion into pediatric, neonate, and new indications, plus supply chain diversification and sales force ramp-up, position the company for continued growth.
CeriBell Earnings Call Transcript: Q2 2025
Q2 2025 revenue grew 38% year-over-year to $21.2 million, driven by commercial expansion and increased adoption. Full-year revenue guidance was raised to $85–$88 million, with gross margins expected in the mid to high 80% range. Legal action was initiated to protect IP, and supply chain risks are being mitigated.
Ceribell Reports Second Quarter 2025 Financial Results
SUNNYVALE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
Ceribell to Report Second Quarter 2025 Financial Results on August 5, 2025
SUNNYVALE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
Ceribell Files Complaints Against Natus Medical Incorporated with the U.S. International Trade Commission and Federal Court in Delaware
Complaints Assert Infringement of Patents Related to Point-of-Care Electroencephalography (EEG) Technology Complaints Assert Infringement of Patents Related to Point-of-Care Electroencephalography (EE...